ITLN1 and obesity disorder: Omentin-1, initially termed as intelectin-1, was suggested as visceral fat-derived adipokine with anti-inflammatory and insulin-sensitizing properties [49] which is reduced in obesity, in a similar manner with adiponectin, and drives the higher burden of excessive body fat in patients with increased cardiovascular risk or type 2 diabetes [7].